CytomX Therapeutics Statistics
Total Valuation
CTMX has a market cap or net worth of $570.90 million. The enterprise value is $246.32 million.
| Market Cap | 570.90M |
| Enterprise Value | 246.32M |
Important Dates
The next estimated earnings date is Thursday, November 5, 2026, after market close.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CTMX has 217.90 million shares outstanding. The number of shares has increased by 88.30% in one year.
| Current Share Class | 217.90M |
| Shares Outstanding | 217.90M |
| Shares Change (YoY) | +88.30% |
| Shares Change (QoQ) | +23.50% |
| Owned by Insiders (%) | 0.57% |
| Owned by Institutions (%) | 88.03% |
| Float | 179.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 30.72 |
| Forward PS | 21.25 |
| PB Ratio | 1.86 |
| P/TBV Ratio | 1.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 12.98 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.36, with a Debt / Equity ratio of 0.02.
| Current Ratio | 9.36 |
| Quick Ratio | 9.26 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -37.75% and return on invested capital (ROIC) is -4,088.61%.
| Return on Equity (ROE) | -37.75% |
| Return on Assets (ROA) | -19.58% |
| Return on Invested Capital (ROIC) | -4,088.61% |
| Return on Capital Employed (ROCE) | -25.53% |
| Weighted Average Cost of Capital (WACC) | 16.21% |
| Revenue Per Employee | $265,261 |
| Profits Per Employee | -$1.20M |
| Employee Count | 69 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CTMX has paid $231,000 in taxes.
| Income Tax | 231,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.67% in the last 52 weeks. The beta is 2.20, so CTMX's price volatility has been higher than the market average.
| Beta (5Y) | 2.20 |
| 52-Week Price Change | -21.67% |
| 50-Day Moving Average | 3.18 |
| 200-Day Moving Average | 4.04 |
| Relative Strength Index (RSI) | 33.52 |
| Average Volume (20 Days) | 4,001,523 |
Short Selling Information
The latest short interest is 38.64 million, so 17.73% of the outstanding shares have been sold short.
| Short Interest | 38.64M |
| Short Previous Month | 33.51M |
| Short % of Shares Out | 17.73% |
| Short % of Float | 21.51% |
| Short Ratio (days to cover) | 11.02 |
Income Statement
In the last 12 months, CTMX had revenue of $18.30 million and -$82.66 million in losses. Loss per share was -$0.45.
| Revenue | 18.30M |
| Gross Profit | 18.30M |
| Operating Income | -87.15M |
| Pretax Income | -79.42M |
| Net Income | -82.66M |
| EBITDA | -86.21M |
| EBIT | -87.15M |
| Loss Per Share | -$0.45 |
Balance Sheet
The company has $330.28 million in cash and $5.70 million in debt, with a net cash position of $324.58 million or $1.49 per share.
| Cash & Cash Equivalents | 330.28M |
| Total Debt | 5.70M |
| Net Cash | 324.58M |
| Net Cash Per Share | $1.49 |
| Equity (Book Value) | 302.07M |
| Book Value Per Share | 1.39 |
| Working Capital | 333.29M |
Cash Flow
In the last 12 months, operating cash flow was -$82.41 million and capital expenditures -$74,000, giving a free cash flow of -$82.48 million.
| Operating Cash Flow | -82.41M |
| Capital Expenditures | -74,000 |
| Depreciation & Amortization | 942,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -82.48M |
| FCF Per Share | -$0.38 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -476.17% |
| Pretax Margin | -433.93% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CTMX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -88.30% |
| Shareholder Yield | -88.30% |
| Earnings Yield | -14.70% |
| FCF Yield | -14.67% |
Analyst Forecast
The average price target for CTMX is $12.25, which is 367.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.25 |
| Price Target Difference | 367.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | -27.86% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CTMX has an Altman Z-Score of 2.72 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.72 |
| Piotroski F-Score | 2 |